Sign up Australia
Proactive Investors - Run By Investors For Investors

Proteomics International Laboratories boosts balance sheet with sale of CPR Pharm Services stake

An MOU between the two companies targeting advanced diagnostics and analytical services for clinical trials remains in place.
Laboratory work
The medical technology company has received $928,399 for the sale

Proteomics International Laboratories Ltd (ASX:PIQ) has boosted its balance sheet with the sale of its shareholding in CPR Pharma Services Pty Ltd for total consideration of $928,399.

The medical technology company has been advised that an offer to purchase all the shares of CPR has been received and accepted by CPR’s majority shareholder.

Sale due to settle later this month

This sale is due to settle on or about September 30, 2018.

In March 2018 Proteomics issued more than 3.868 million ordinary shares at a deemed issue price of 30.45 cents to acquire 10% of the fully diluted issued share capital of CPR.

The sale, therefore, equates to receipt of 24 cents per PIQ share issued with shares currently trading at around 26 cents.

MOU remains in place

An MOU between Proteomics and CPR remains in place, targeting advanced diagnostics and analytical services for clinical trials.

Proteomics International, which operates from state-of-the-art facilities on Perth’s QEII Medical Campus, is at the forefront of predictive diagnostics and bioanalytical services.

It specialises in the area of proteomics – the industrial scale study of the structure and function of proteins.

View full PIQ profile View Profile

Proteomics International Laboratories Ltd Timeline

Related Articles

car-t cells definition
17:15
The phase I clinical study will evaluate the safety of MaxCyte's MCY-M11 chimeric antigen receptor in people with relapsed or difficult-to-treat ovarian cancer and peritoneal mesothelioma
Skin beauty
April 19 2018
In a note to clients initiating coverage on SkinBio, the joint ‘house’ broker noted that, as the skin microbiome group operates in a new therapeutic area, there is little market data in the sector
1537236236_main-better-use.jpg
Tue
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use